Given the lack of selective SMARCA2 or SMARCA4 inhibitors, we treated a panel of ADRN-type NB cell lines with the SMARCA2/4 dual PROTAC degraders ACBI1 or AU-15330. Here, SMARCA2 is linked to neuroblastoma.